Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Previously Presented). A compound comprising two individual peptide sequences, wherein at least one of the two individual peptide sequences comprises an amino acid sequence of the formula

L1-A-L2-B-L3-C-L4-D-L5
wherein
one of A, B, C, D is selected from a hydrophobic amino acid residue,
one of A, B, C, D is selected from a basic amino acid residue, Asn or Gln,
one of A, B, C, D is selected from an acidic amino acid residue, Asn or Gln,
one of A, B, C, D is Gly or Ala, and
L1, L2, L3, L4 and L5 is selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5,
wherein
said peptide sequences are connected to each other through a linker of the formula

X[(A)nCOOH][(B)mCOOH]

n and m independently are an integer of from 1 to 20,
X is HN, $H_2N(CR_2)pCR$, $RHN(CR_2)pCR$, $HO(CR_2)pCR$, $HS(CR_2)pCR$, halogen-$(CR_2)pCR$, $HOOC(CR_2)pCR$, $ROOC(CR_2)pCR$, $HCO(CR_2)pCR$, $RCO(CR_2)pCR$,

[HOOC(A)n][HOOC(B)m]CR(CR_2)pCR, $H_2N(CR_2)p$, $RHN(CR_2)p$, $HO(CR_2)p$, $HS(CR_2)p$, halogen-$(CR_2)p$, $HOOC(CR_2)p$, $ROOC(CR_2)p$, $HCO(CR_2)p$, $RCO(CR_2)p$, or [HOOC(A)n][HOOC(B)m]$(CR_2)p$, wherein p is 0 or integer of from 1 to 20,

A and B independently are a substituted or unsubstituted C_{1-10} alkyl, a substituted or unsubstituted C_{2-10} alkenyl, a substituted or unsubstituted cyclic moiety, a substituted or unsubstituted heterocyclic moiety, a substituted or unsubstituted aromatic moiety, or A and B together form a substituted or unsubstituted cyclic moiety, substituted or unsubstituted heterocyclic moiety, or substituted or unsubstituted aromatic moiety.

2 (Previously Presented). The compound according to claim 1, wherein the at least one of the two peptide sequences is capable of binding to a functional cell surface receptor.

3 (Currently Amended). The compound according to claim 2, wherein the functional cell surface receptor is a receptor selected from the family of fibroblast growth factor receptors (FGFRs) ~~comprising~~ consisting of FGFR1, FGFR2, FGFR3 and FGFR4.

4 (Currently Amended). The compound according to claim 2, wherein the at least one of the two peptide sequences is derived from the sequence of a polypeptide selected from the group ~~comprising~~ consisting of cell adhesion molecules, cell-surface receptors, heparan sulphate proteoglycans, and metalloproteases, extracellular matrix molecules or growth factors.

5 (Currently Amended). The compound according to ~~the~~ claim 4, wherein the cell adhesion molecule is selected from the group ~~comprising~~ consisting of

Neural Cell Adhesion Molecule (NCAM) (Swiss-Prot Ass. Nos: P13591, P13595-01, P13595),

Neural cell adhesion molecule L1 (Swiss-Prot Ass. Nos: Q9QYQ7, Q9QY38,

P11627, Q05695, P32004),

Neural Cell Adhesion Molecule-2 (NCAM-2) (Swiss-Prot Ass. No: P36335)

Neuron-glia Cell Adhesion Molecule (Ng-CAM) (Swiss-Prot Ass. No: Q03696; Q90933),

Neural cell adhesion molecule CALL (Swiss-Prot Ass. No: O00533),

Neuroglian (Swiss-Prot Ass. No: P91767, P20241),

Nr-CAM (HBRAVO, NRCAM, NR-CAM 12) (Swiss-Prot Ass. Nos: Q92823, O15179, Q9QVN3

Axonin-1/TAG-1 (Swiss-Prot Ass. Nos: Q02246, P22063, P28685),

Axonal-associated Cell Adhesion Molecule (AxCAM) (NCBI Ass. No: NP_031544.1; Swiss-Prot Ass. No: Q8TC35),

Myelin-Associated Glycoprotein (MAG) (Swiss-Prot Ass. No: P20917),

Neural cell adhesion molecule BIG-1 (Swiss-Prot Ass. No: Q62682),

Neural cell adhesion molecule BIG-2 (Swiss-Prot Ass. No: Q62845),

Fasciclin (FAS-2) (Swiss-Prot Ass. No: P22648),

Neural cell adhesion molecule HNB-3/NB-3 (Swiss-Prot Ass. Nos: Q9UQ52, P97528, Q9JMB8)

Neural cell adhesion molecule HNB-2/NB-2 (Swiss-Prot Ass. Nos: O94779, P07409, P97527),

Cadherin (Swiss-Prot Ass. No: Q9VW71),

Junctional Adhesion Molecule-1 (JAM-1) (Swiss-Prot Ass. Nos: Q9JKD5, O88792),

Neural cell adhesion F3/F11(Contactin) (Swiss-Prot Ass. Nos: Q63198, P1260, Q12860, Q28106, P14781, O93250),

Neurofascin (Swiss-Prot Ass. Nos: Q90924, Q91Z60; O42414),

B-lymphocyte cell adhesion molecule CD22 (Swiss-Prot Ass. Nos: Q9R094, P20273),

Neogenin (NEO1) (Swiss-Prot Ass. Nos: Q92859, P97603, Q90610, P97798),

Intercellular Cell Adhesion Molecule-5 (ICAM-5/telencephalin) (Swiss-Prot Ass. Nos: Q8TAM9, Q60625) or

Galactose binding lectin-12 (galectin-12) (Swiss-Prot Ass. Nos: Q91VD1, Q9JKX2, Q9NZ03) and

Galactose binding lectin-4 (galectin-4) (Swiss-Prot Ass. No: Q8K419; P38552).

6 (Currently Amended). The compound according to ~~the~~ claim 4, wherein the cell-surface receptor is selected from the group ~~comprising~~ consisting of

Fibroblast Growth Factor Receptor 1 (FGFR1) (Swiss-Prot Ass. Nos: Q9QZM7, Q99AVV7, Q9UD50, Q63827),

Fibroblast Growth Factor Receptor 2 (FGFR2) (Swiss-Prot Ass. Nos: Q96KM2, P21802, Q63241),

Fibroblast Growth Factor Receptor 3 (FGFR3) (Swiss-Prot Ass. Nos: Q95M13, AF487554, Q99052),

Fibroblast Growth Factor Receptor 4 (FGFR4) (Swiss-Prot Ass. No: Q91742),

Neurotrophin Tyrosin Kinase Type-2 (NTRKT-2) (Swiss-Prot Ass. No: Q8WXJ5),

Leukocyte Antigen Related Protein-Tyrosine Phosphatase (LAR-PTPRF) (Swiss-Prot Ass. Nos: Q9EQ17, Q64605, Q64604, Q9QW67, Q9VIS8 P10586),

Nephrin (Swiss-Prot Ass. Nos: Q925S5, Q9JIX2, Q9ET59, Q9R044, Q9QZS7, Q06500),

Protein-Tyrosine Phosphatase Receptor type S (PTPRS) (Swiss-Prot Ass. Nos: Q64699, Q13332, O75870),

Protein-Tyrosine Phosphatase Receptor type kappa (R-PTP-kappa) (Swiss-Prot Ass. No: Q15262),

Protein-Tyrosine Phosphatase Receptor type D (PTPRD) (Swiss-Prot Ass. Nos: Q8WX65, Q9IAJ1, P23468, Q64487),

Ephrin type-A receptor 8 (EPHA8/Tyrosine-Protein Kinase Receptor EEK) (Swiss-Prot Ass. Nos: O09127, P29322),

Ephrin type-A receptor 3 (EPHA8/Tyrosine-Protein Kinase Receptor ETK-1/CEK4) (Swiss-Prot Ass. No: P29318),

Ephrin type-A receptor 2 (Swiss-Prot Ass. No: Q8N3Z2)

Insulin Receptor (IR) (Swiss-Prot Ass. No: Q9PWN6)

Insulin-like Growth Factor-1 Receptor (IGF-1) (Swiss-Prot Ass. Nos: Q9QVW4, P08069, P24062, Q60751, P15127, P15208)

Insulin-related Receptor (IRR) (Swiss-Prot Ass. No: P14616),

-Tyrosine-Protein Kinase Receptor Tie-1 (Swiss-Prot Ass. Nos: 06805, P35590, Q06806),

Roundabout receptor-1 (robo-1) (Swiss-Prot Ass. Nos: O44924, AF041082, Q9Y6N7),

Neuronal nicotinic acetylcholine receptor alpha 3 subunit (CHRNA3) (Swiss-Prot Ass. Nos: Q8VHH6, P04757, Q8R4G9, P32297)

Neuronal acetylcholine receptor alpha 6 subunit (Swiss-Prot Ass. Nos: Q15825, Q9R0W9)

Platelet-Derived Growth Factor Receptor Beta (PDGFRB) (Swiss-Prot Ass. Nos: Q8R406, Q05030),

Interleukin-6 Receptor (IL-6R) (Swiss-Prot Ass. No: Q00560),

Interleukin-23 Receptor (IL-23R) (Swiss-Prot Ass. No: AF461422),

Beta-common cytokine receptor of IL-3, IL5 and GmCsf (Swiss-Prot Ass. No: P32927)

Cytokine Receptor-Like molecule 3 (CRLF1) (Swiss-Prot Ass. No: Q9JM58),

Class I Cytokine Receptor (ZCYTOR5) (Swiss-Prot Ass. No: Q9UHH5)

Netrin-1 receptor DCC (Swiss-Prot Ass. No: P43146),

Leukocyte Fc Receptor-like Protein (IFGP2) (Swiss-Prot Ass. Nos: Q96PJ6, Q96KM2),

Macrophage Scavenger Receptor 2 (MSR2) (Swiss-Prot Ass. No: Q91YK7) and

Granulocyte Colony Stimulating Factor Receptor (G-CSF-R) (Swiss-Prot Ass. No: Q99062).

7 (Currently Amended). The compound according to ~~the~~ claim 4, wherein the heparan sulphate proteoglycan is perlecan (Swiss-Prot Ass. No: P98160).

8 (Currently Amended). The compound according to ~~the~~ claim 4, wherein the metalloprotease is selected from the group ~~comprising~~ consisting of

ADAM-8 (Swiss-Prot Ass. No: Q05910),

ADAM-19 (Swiss-Prot Ass. Nos: Q9H013, O35674),

ADAM-8 (Swiss-Prot Ass. No: P78325),

ADAM-12 (Swiss-Prot Ass. Nos: O43184, Q61824),

ADAM-28 (Swiss-Prot Ass. Nos: Q9JLN6, Q61824, Q9XSL6, Q9UKQ2),

ADAM-33 precursor (Swiss-Prot Ass. Nos: Q8R533, Q923W9),

ADAM-9 (Swiss-Prot Ass. Nos: Q13433, Q61072),

ADAM-7 (Swiss-Prot Ass. NoS: Q9H2U9, O35227, Q63180),

ADAM-1A Fertilin alpha (Swiss-Prot Ass. No: Q8R533),

ADAM-15 (Swiss-Prot Ass. Nos: Q9QYV0, O88839, Q13444),

Metalloproteinase-desintegrin domain containing protein (TECAM) (Swiss-Prot Ass. No: AF163291), and

Metalloproteinase 1 (Swiss-Prot Ass. Nos: O95204, Q9BSI6).

9 (Currently Amended). The compound according to ~~the~~ claim 4, wherein the extracellular matrix molecule is selected from the group ~~comprising~~ consisting of

Collagen type VII (Swiss-Prot Ass. No: Q63870),

Fibronectin (Swiss-Prot Ass. Nos: Q95KV4, Q95KV5, P07589, Q28377, U42594, O95609, P11276), ~~or~~ and

Tenascin-R (Swiss-Prot Ass. Nos: Q15568, O00531, Q90995, P10039).

10 (Currently Amended). The compound according to ~~the~~ claim 4, wherein the growth factor is Cytokine-like factor-1 (CLF-1) (Swiss-Prot Ass. No:O75462).

11 (Currently Amended). The compound according to ~~any of the~~ claims 1 ~~to 10~~, wherein the at least one of the two peptide sequences is a peptide fragment having the amino acid sequence selected from the group consisting of

EVYVVAENQQGKSKA (SEQ ID NO 1),
NIEVWVEAENALGKKV (SEQ ID NO: 2),
ATNRQGKVKAFAHL (SEQ ID NO: 3),
RYVELYVVADSQEFQK (SEQ ID NO: 4)
VAENSRGKNVAKG (SEQ ID NO: 5),
GEYWCVAENQYGQR (SEQ ID NO: 6),
RLAALNGKGLGEIS (SEQ ID NO: 7),
KYIAENMKAQNVAKEI (SEQ ID NO: 8),
TIMGLKPETRYAVR (SEQ ID NO: 9),
KGLGEISAATEFKT (SEQ ID NO: 10),
NMGIWVQAENALG (SEQ ID NO: 11),
IWVQAENMLG (SEQ ID NO: 12),
EIWVEATNRLG (SEQ ID NO: 13),
VWVQAANALG (SEQ ID NO: 14),

EVWIEKDPAKGRI (SEQ ID NO: 15),
ATNKGGEVKKNGHL (SEQ ID NO: 16),
KYVELYLVADYLEFQK (SEQ ID NO: 17),
RYVELYVVVDNAEFQ (SEQ ID NO: 18),
KYVELVIVADNREFQR (SEQ ID NO: 19),
KYIEYYLVLDNGEFKR (SEQ ID NO: 20),
RYLELYIVADHTLF (SEQ ID NO: 21),
KYVEMFVVVNHQRFQ (SEQ ID NO: 22) ,
RYVELFIVVDKERY (SEQ ID NO: 23),
KYVELFIVADDTVYRR (SEQ ID NO: 24),
KFIELFVVADEYVYRR (SEQ ID NO: 25),
KIVEKVIVADNSEVRK (SEQ ID NO: 26),
VELVIVADHSEAQK (SEQ ID NO: 27),
VAENSRGKNIAKG (SEQ ID NO: 28),
IAENSRGKNVARG (SEQ ID NO: 29),
AENSRGKNSFRG (SEQ ID NO: 30),
IASNLRGRNLAKG (SEQ ID NO: 31),
IPENSLGKTYAKG (SEQ ID NO: 32),
IAENMKAQNEAK (SEQ ID NO: 33),
QFIAENMKSHNETKEV (SEQ ID NO: 34),
GEYWCVAKNRVGQ (SEQ ID NO: 35),
GSYTCVAENMVGK (SEQ ID NO: 36),
GKYVCVGTNMVGER (SEQ ID NO: 37),
GNYTCVVENEYG (SEQ ID NO: 38),
GEYTCLAGNSIG (SEQ ID NO: 39),
QYYCVAENGYG (SEQ ID NO: 40),
GEYYQEAEQNGYG (SEQ ID NO: 41),

GNYTCLVENEYG (SEQ ID NO: 42),
GMYQCLAENAYG (SEQ ID NO: 43),
GMYQCAENTHG (SEQ ID NO: 44),
GIYYCLASNNYG (SEQ ID NO: 45),
GGYYCTADNSYG (SEQ ID NO: 46),
GEYQCFARNDYG (SEQ ID NO: 47),
GEYFCLASNKMG (SEQ ID NO: 48),
GEYQCFARNKFG (SEQ ID NO: 49),
GEYFCLASNKMG (SEQ ID NO: 50),
GGYYCTADNNYG (SEQ ID NO: 51),
GNYSCEAENAWGTK (SEQ ID NO: 52),
GEYTCLAENSLG (SEQ ID NO: 53),
GEYECVAENGRLG (SEQ ID NO: 54),
GNYTCVVENKFGR (SEQ ID NO: 55),
GEYTCLAGNSIG (SEQ ID NO: 56),
GEYFCVASNPIG (SEQ ID NO: 57),
EYTCIANNQAGE (SEQ ID NO: 58),
GMYQCVAENKHLG (SEQ ID NO: 59),
GEYMCTASNTIGQ (SEQ ID NO: 60),
EYVCIAENKAGEQ (SEQ ID NO: 61),
GDYTLIAKNEYGK (SEQ ID NO: 62),
GFYQCVAENEAG (SEQ ID NO: 63),
GKYECVATNSAGTR (SEQ ID NO: 64),
GEYFCVYNNSLG (SEQ ID NO: 65),
GEYECAATNAHGR (SEQ ID NO: 66),
GAYWCQGTNSVGK (SEQ ID NO: 67),
GTYSCVAENILG (SEQ ID NO: 68),

RVAAVNGKGQGDYS (SEQ ID NO: 69),
RVAAINGCGIGPFS (SEQ ID NO: 70),
AVLNGKGLG (SEQ ID NO: 71),
ALNGQGLGATS (SEQ ID NO: 72),
RLAAKNRAGLGE (SEQ ID NO: 73),
RLGVVTGKDLGEI (SEQ ID NO: 74),
TVTGLKPETSYMVK (SEQ ID NO: 75),
TLTGLKPSTRYRI (SEQ ID NO: 76),
TLTGLQPSTRYRV (SEQ ID NO: 77),
TLLGLKPDTTYDIK (SEQ ID NO: 78),
TLQGLRPETAYELR (SEQ ID NO: 79),
TLRGLRPETAYELR (SEQ ID NO: 80),
TLMNLRPKTGYSVR (SEQ ID NO: 81),
TVSGLKPGTRY (SEQ ID NO: 82),
TISGLKPDTTY (SEQ ID NO: 83),
TLQGLKPDTAY (SEQ ID NO: 84),
LRGLKPWTQYAV (SEQ ID NO: 85),
IDGLEPDTEYIVR (SEQ ID NO: 86),
LQGLKPWTQYAI (SEQ ID NO: 87),
TITGLEPGTEYTIQ (SEQ ID NO: 88),
GLKPWTQYAV (SEQ ID NO: 89),
TLASLKPWTQYAV (SEQ ID NO: 90),
LMGLQPATEYIV (SEQ ID NO: 91),
KGMGPMSEAVQFRT (SEQ ID NO: 92),
TLTGLKPDTTYDVK (SEQ ID NO: 93),
ISGLQPETSYSL (SEQ ID NO: 94),
TLLGLKPDTTYDIK (SEQ ID NO: 95),

TISGLTPETTYSI (SEQ ID NO: 96),
GNYSCLAENRLGR (SEQ ID NO: 97),
GNYTCVVENRVG (SEQ ID NO: 98),
GTYHCVATNAHG (SEQ ID NO: 99),
LSHNGVLTGYLLSY (SEQ ID NO: 100),
NGVLTGYVLRY (SEQ ID NO: 101),
NGVLTGYNLRY (SEQ ID NO: 102),
NGNLTGYLLQY (SEQ ID NO: 103),
VDENGVLTGYKIYY (SEQ ID NO: 104),
THNGALVGYSVRY (SEQ ID NO: 105),
NGILTEYILKY (SEQ ID NO: 106),
NGILIGYTLRY (SEQ ID NO: 107),
THSGQITGYKIRY (SEQ ID NO: 108),
NGKITGYIIYY (SEQ ID NO: 109),
LSHNGIFTLY (SEQ ID NO: 110),
NGILTEYTLKY (SEQ ID NO: 111),
LDPNGIITQYEISY (SEQ ID NO: 112),
NGKITGYIIYY (SEQ ID NO: 113),
HLEVQAFNGRGSGPA (SEQ ID NO: 114),
HLTVRAYNGAGYGP (SEQ ID NO: 115),
HLSVKAYNSAGTGPS (SEQ ID NO: 116),
HLAVKAYNSAGTGPS (SEQ ID NO: 117),
NLEVRAFNSAGDGP (SEQ ID NO: 118),
HLTVLAYNSKGAGP (SEQ ID NO: 119),
LRVLVFNGRGDGP (SEQ ID NO: 120),
HIDVSAFNSAGYGP (SEQ ID NO: 121),
HLAVELFNGR (SEQ ID NO: 122),

LELQSINFLGGQPA (SEQ ID NO: 123),
HFTVRAYNGAGYGP (SEQ ID NO: 124),
HLEVQAFNGRGSQPA (SEQ ID NO: 125),
VIADQPTFVKYLIK (SEQ ID NO: 126),
TIKGLRPGVVYEGQ (SEQ ID NO: 127),
TLTELSPSTQYTVK (SEQ ID NO: 128),
TLDDLAPDTTYLVQ (SEQ ID NO: 129),
TVSDVTPHAIYTVR (SEQ ID NO: 130),
IIRGLNASTRYLFR (SEQ ID NO:131),
TLMNLRPKTGYSVR (SEQ ID NO:132),
TLTGLKPGTEYEVR (SEQ ID NO: 133),
GPEHLMPSSTYVAR (SEQ ID NO: 134),
RVTGLTPKKTYEFR (SEQ ID NO: 135),
LTGLKPGTEYEFR (SEQ ID NO: 136),
EVRVQAVNGGGNGPP (SEQ ID NO: 137),
LIKVVAINDRGE (SEQ ID NO: 138),
VVSIIAVNGREE (SEQ ID NO: 139),
VVSVYAQNQNGE (SEQ ID NO: 140),
TISLVAEKGRHK (SEQ ID NO: 141),
HLEVQAFNGRGSGPA (SEQ ID NO: 142),
HVEVQAFNGRGLGPA (SEQ ID NO: 143),
HVEVQAFNGRGLGPA (SEQ ID NO: 144),
EFRVRAVNGAGEG (SEQ ID NO: 145), ~~or~~ and
VARVRTRLAPGSRLS (SEQ ID NO: 146), ~~or~~
or a fragment, or a variant, or homologue thereof,
wherein

said fragment is an amino acid sequence which has at least 40% of the length of a sequence selected from the group consisting of SEQ ID NOs:1-146 and which is capable of binding to fibroblast growth factor receptor,
said variant is an amino acid sequence which has at least 60% of homology to a sequence selected from the group consisting of SEQ ID NOs: 1-146 and which is capable of binding to fibroblast growth factor receptor, and
said homologue is an amino acid sequence which has at least 20% homology to a sequence selected from the group consisting of SEQ ID NOs: 1-146 and which is capable of binding to fibroblast growth factor receptor.

12 (Currently Amended). The compound according to claims 1 ~~to 10~~, wherein the at least one of the two peptide sequences is SEQ ID NO: 1 (EVYVVAENQQGKSKA), or a fragment, variant, or homologue of said sequence.

13 (Currently Amended). The compound of claim 12, wherein the variant or homologue of SEQ ID NO: 1 is selected from the group consisting of SEQ ID NOs: 2-9, 100 ~~or~~ and [[125]]~~,~~.

14 (Currently Amended). The compound according to claims 1 ~~to 10~~, wherein the at least one of the two peptide sequences is SEQ ID NO: 2 (NIEVWVEAENALGKKV), or a fragment, variant or homologue of said sequence.

15 (Currently Amended). The compound according to ~~any of the preceding~~ claims 1, wherein the compound comprises two individual peptide fragments comprising different amino acid sequences, said different amino acid sequences being selected ~~from any of the peptide fragments of claim 11~~ independently from said group of amino acid sequences.

16 (Currently Amended). The compound according to ~~any of the preceding~~ claims 1, wherein the compound comprises two peptide fragments comprising the identical amino acid sequence, said amino acid sequence being selected from ~~any of the peptide fragments of claim 11~~ said group of amino acid sequences.

17 (Currently Amended). The compound according to claim 16, wherein the peptide fragments ~~are independently having~~ have the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1).

18 (Currently Amended). The compound according to claim 16, wherein the peptide fragments ~~are independently having~~ have the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

19 (Currently Amended). The compound according to claim 15, wherein one of the two peptide fragments ~~is having~~ has the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1), and the other ~~is having~~ has the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

20 (Currently Amended). The compound according to ~~any of the preceding~~ claims 11, said compound being obtained by a method ~~for preparing an LPA enabling presentation of sequence(s) as defined in claim 11~~ comprising the steps of

providing by solid phase synthesis or fragment coupling ligands comprising desired sequence(s), the ligands being attached to a solid phase,

if nessesary, deprotecting any N-terminal amino acid groups while th eligands/s) are still attached to the solid phase,

reacting the ligand(s) having unprotected N-terminal groups with an achiral di- tri- or tetracarboxylic acid so as to provide a construct having a ring structure, and

cleaving the construct from the solid phase so as to provide an LPA comprising ligands having free C-terminal groups.

21 (Currently Amended). A pharmaceutical composition comprising a compound as defined in claims 1-~~20~~.

22 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1-~~20~~ ~~for the manufacture of a medicament~~ for treatment of conditions of the central and peripheral nervous system associated with postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, ~~e.g. resulting from a stroke~~, Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias ~~such as multiinfarct dementia~~, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia, mood disorders~~, such as manic depression~~; for treatment of diseases or conditions of the muscles ~~including conditions with impaired function of neuro-muscular connections, such as after organ transplantation, or such as genetic or traumatic atrophic muscle disorders~~; or for treatment of diseases or conditions of ~~various organs, such as degenerative conditions of~~ the gonads, ~~of the~~ pancreas ~~such as diabetes mellitus type I and II~~, ~~of the~~ kidney ~~such as nephrosis and of the~~ ,heart, liver ~~and~~ or bowel.

23 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1-~~20~~ ~~for the manufacture of a medicament~~ for the treatment of postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, ~~e.g. resulting from a stroke~~, Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias ~~such as multiinfarct dementia~~, sclerosis, nerve degeneration associated with diabetes mellitus,

disorders affecting the circadian clock or neuro-muscular transmission, ~~and~~ schizophrenia, or mood disorders~~, such as manic depression~~.

24 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1~~-20 for the manufacture of a medicament~~ for the promotion of wound-healing.

25 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in claims 1~~-20 for the manufacture of a medicament~~ for the treatment of cancer.

26 (Currently Amended). The ~~use~~ method of treatment according to claim 25, wherein the cancer is any type of solid tumors requiring neoangiogenesis.

27 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1~~-20 for the manufacture of a medicament~~ for the prevention of death of heart muscle cells, ~~such as after acute myocardial infarction, or after angiogenesis~~.

28 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of~~ claims 1~~-20 for the manufacture of a medicament~~ for ~~revascularsation~~ revascularization.

29 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1~~-20 for the manufacture of a medicament~~ for the stimulation of the ability to learn and/or the short and/or long-term memory.

30 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1~~-20 for the manufacture of a medicament~~ for the prevention of cell death due to ischemia.

31 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1~~-20 for the manufacture of a medicament~~ for the prevention of body damages due to alcohol consumption.

32 (Currently Amended). ~~Use~~ Method of treatment comprising administering an effective amount of a compound as defined in ~~any of the~~ claims 1~~-20 for the manufacture of a medicament~~ for the treatment of prion diseases.

33-34 (Cancelled).